LANCASTER, CA, August 14, 2006 - Simulations Plus, Inc. (AMEX: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, reminds shareholders that the 2-for-1 stock split declared by the board of directors has now taken effect and that beginning today, August 14, 2006, the company's common stock is trading at the post-split price.
Momoko Beran, chief financial officer of Simulations Plus, said, "The split will have the effect of increasing the public float and it is hoped, thereby increasing trading volume and liquidity, making our stock more attractive to a larger investor community, although there can be no assurances that the split will have such an effect."
The Company also announced that Walt Woltosz, chairman and chief executive officer of Simulations Plus, will participate in an interview with the Wall Street Reporter on Tuesday, August 15, in response to a request by the Wall Street Reporter.
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The Company's Words+ subsidiary produces assistive technology and communication devices for persons with disabilities. The Company also produces a line of educational simulation software under the umbrella name FutureLab(TM), which is based on its proprietary software technologies. Simulations Plus, Inc., is headquartered in Southern California. For more information, visit our Web sites at www.simulations-plus.com and www.words-plus.com.
For further information:
Simulations Plus, Inc.
42505 10th Street West
Lancaster, CA
93534-7059 USA
www.simulations-plus.com
CONTACT: investor relations:
Contact: Renee Bouche